Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

1.

Unknown HIV Status in the Emergency Department: Implications for Expanded Testing Strategies.

Felsen UR, Bellin EY, Cunningham CO, Zingman BS.

J Int Assoc Provid AIDS Care. 2015 May 21. pii: 2325957415586261. [Epub ahead of print]

PMID:
25999330
2.

Development of an electronic medical record-based algorithm to identify patients with unknown HIV status.

Felsen UR, Bellin EY, Cunningham CO, Zingman BS.

AIDS Care. 2014;26(10):1318-25. doi: 10.1080/09540121.2014.911813. Epub 2014 Apr 30.

PMID:
24779521
3.

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, Infectious Diseases Society of America.

Clin Infect Dis. 2014 Jan;58(1):1-10. doi: 10.1093/cid/cit757.

4.

Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman BS, Sarlo J, Gorny MK, Zolla-Pazner S, Robinson JE, Pinter A.

Virology. 2014 Jan 5;448:363-74. doi: 10.1016/j.virol.2013.10.007. Epub 2013 Nov 12.

5.

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, Infectious Diseases Society of America.

Clin Infect Dis. 2014 Jan;58(1):e1-34. doi: 10.1093/cid/cit665. Epub 2013 Nov 13.

6.

Apathy correlates with cognitive performance, functional disability, and HIV RNA plasma levels in HIV-positive individuals.

Shapiro ME, Mahoney JR, Zingman BS, Pogge DL, Verghese J.

J Clin Exp Neuropsychol. 2013;35(9):934-45. doi: 10.1080/13803395.2013.838941. Epub 2013 Oct 4.

7.

Cognitive reserve protects against apathy in individuals with human immunodeficiency virus.

Shapiro ME, Mahoney JR, Peyser D, Zingman BS, Verghese J.

Arch Clin Neuropsychol. 2014 Feb;29(1):110-20. doi: 10.1093/arclin/act071. Epub 2013 Sep 9.

8.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team.

Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum in: Lancet. 2014 Jan 4;383(9911):30.

PMID:
23830355
9.

Sequential antiretroviral adherence measurement using electronic bottle cap monitors in a cohort of HIV-infected adults.

Shuter J, Sarlo JA, Stubbs RO, Rode RA, Zingman BS.

J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr;11(2):94-7. doi: 10.1177/1545109711420498. Epub 2012 Jan 5.

PMID:
22223595
10.

Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Ma Q, Zingman BS, Luque AE, Fischl MA, Gripshover BM, Venuto CS, DiFrancesco R, Forrest A, Morse GD.

Ther Drug Monit. 2011 Jun;33(3):309-14. doi: 10.1097/FTD.0b013e31821d3adb.

11.

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.

12.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.

13.

Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

Suleiman J, Zingman BS, Diaz RS, Madruga JV, DeJesus E, Slim J, Mak C, Lee E, McCarthy MC, Dunkle LM, Walmsley S.

J Infect Dis. 2010 Feb 15;201(4):590-9. doi: 10.1086/650342.

14.

Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.

Shuter J, Sarlo JA, Rode RA, Zingman BS.

HIV Clin Trials. 2009 May-Jun;10(3):135-42. doi: 10.1310/hct1003-135.

PMID:
19632952
15.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

16.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

17.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169.

18.

Withdrawal of Pneumocystis prophylaxis.

Zingman BS, Grossberg R.

AIDS. 2008 Jan 11;22(2):323-4; author reply 324. Review. No abstract available.

PMID:
18097244
19.

Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.

Higgins N, Zingman BS, Slish J, Reichman RC, Fischl MA, Gripshover B, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD.

Am J Addict. 2007 Nov-Dec;16(6):488-94.

PMID:
18058416
20.

Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD.

Ther Drug Monit. 2007 Oct;29(5):560-5.

PMID:
17898644
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk